Homepage
Author:
Aspire Biopharma Holdings, Inc.
Posted Date:
March 19, 2026
Aspire Biopharma’s Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
Aspire Biopharma Holdings, Inc.
March 19, 2026
Aspire Biopharma’s Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
Aspire Biopharma Holdings, Inc.
March 17, 2026
Aspire Biopharma’s Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
Aspire Biopharma Holdings, Inc.
March 12, 2026
Aspire Biopharma’s BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
Aspire Biopharma Holdings, Inc.
March 10, 2026
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
Aspire Biopharma Holdings, Inc.
March 3, 2026
Aspire Biopharma’s Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
Aspire Biopharma Holdings, Inc.
February 25, 2026
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Aspire Biopharma Holdings, Inc.
February 20, 2026
Aspire Biopharma’s Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
Aspire Biopharma Holdings, Inc.
February 19, 2026
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
Aspire Biopharma Holdings, Inc.
February 17, 2026
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
Aspire Biopharma Holdings, Inc.
February 13, 2026
1
2
Next
